Urinary proteomics in the assessment of chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 6, 2011, Pages 654-661

  Mullen, William ^a   Delles, Christian ^a   Mischak, Harald ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Mosaiques Diagnostics GmbH   (Germany)

Author keywords

biomarker; chronic kidney disease; diabetic nephropathy; proteome; urine

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; CREATININE; IRBESARTAN; NEUTROPHIL COLLAGENASE; PLACEBO; PROTEOME; TAMM HORSFALL GLYCOPROTEIN;

AGING; ANCA ASSOCIATED VASCULITIS; BIOACCUMULATION; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SURVEILLANCE; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROALBUMINURIA; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; UPREGULATION; URINALYSIS;

AGING; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEINURIA; PROTEOME; PROTEOMICS; RENAL INSUFFICIENCY, CHRONIC;

EID: 80054724587     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834b7ffa     Document Type: Review

References (44)

1. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38:1933-1953.
2. Redon J, Pascual JM. Development of microalbuminuria in essential hypertension. Curr Hypertens Rep 2006; 8:171-177. (Pubitemid 43803132)
3. Redon J, Rodicio JL Microalbuminuria in type 1 diabetes mellitus. J Hypertens 2004; 22:1425-1428. (Pubitemid 38888093)
4. Karalliedde J, Viberti G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol 2010; 21:2020-2027.
5. MacIsaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011; 20:246-257.
6. Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010; 2:46-42.
7. Mischak H, Rossing P. Proteomic biomarkers in diabetic nephropathy: reality or future promise? Nephrol Dial Transplant 2010; 25:2843-2845.
8. Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007; 18:1057-1071. (Pubitemid 46536892)
9. Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 2007; 6:4549-4555.
10. Decramer S, Zürbig P, Wittke S, et al. Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy. Contrib Nephrol 2008; 160:127-141.
11. Mischak H, Schiffer E, Zuerbig P, et al. Urinary proteome analysis using capillary electrophoresis coupled mass spectrometry: a powerful tool in clinical diagnosis, prognosis and therapy evaluation. J Med Biochem 2009; 28:223-234.
12. Good DM, Zürbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9:2424-2437.
13. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48:1439-1444. (Pubitemid 41175492)
14. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19:1283-1290.
15. Snell-Bergeon JK, Maahs DM, Ogden LG, et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009; 11:1-9.
16. Alkhalaf A, Zurbig P, Bakker SJ, et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010; 5:e13421.
17. Lapolla A, Seraglia R, Molin L, et al. Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephro-pathic patients: a MALDI study. J Mass Spectrom 2009; 44:419-425.
18. Lapolla A, Molin L, Sechi A, et al. A further investigation on a MALDI-based method for evaluation of markers of renal damage. J Mass Spectrom 2009; 44:1754-1760.
19. Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20:2065-2074.
20. Kistler AD, Mischak H, Poster D, et al. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 2009; 76:89-96.
21. Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006; 12:398-400.
22. Drube J, Zurbig P, Schiffer E, et al. Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol 2010; 25:1673-1678.
23. Sigdel T, Kaushal A, Gritsenko M, et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin Appl 2010; 4:32-47.
24. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol 2010; 21:646-653.
25. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int 2010; 78:1252-1262.
26. Metzger J, Chatzikyrkou C, Broecker V, et al. Diagnosis of subclinical and clinical acute T-cell mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl 2011; 5:322-333.
27. Haubitz M, Good DM, Woywodt A, et al. Identification and validation of urinary biomarkers for differential diagnosisand evaluation of therapeutic intervention in ANCA associated vasculitis. Mol Cell Proteomics 2009; 8:2296-2307.
28. Andersen S, Mischak H, Zurbig P, et al. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010; 11:29.
29. Zürbig P, Decramer S, Dakna M, et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009; 9:2108-2117.
30. Dominiczak AF, Herget-Rosenthal S, Delles C, et al. Systems biology to battle vascular disease. Nephrol Dial Transplant 2010; 25:1019-1022.
31. Candiano G, Musante L, Bruschi M, et al. Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol 2006; 17:3139-3148. (Pubitemid 44707774)
32. Rossing K, Mischak H, Rossing P, et al. The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2:997-1007.
33. Haubitz M, Wittke S, Weissinger EM, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005; 67:2313-2320. (Pubitemid 41623391)
34. Thongboonkerd V, Barati MT, McLeish KR, et al. Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. J Am Soc Nephrol 2004; 15:650-662. (Pubitemid 38294795)
35. Zurbig P, Dihazi H, Metzger J, et al. Urine proteomics in kidney and urogenital diseases: moving towards clinical applications. Proteomics Clin Appl 2011; 5:256-268.
36. Mischak H, Coon JJ, Novak J, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009; 28:703-724.
37. Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010; 17:493-506.
38. Siwy J, Mullen W, Golovko I, Franke J, Zuerbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 2011; 5:367-374.
39. Vlahou A, Allmaier G, Attwood T, et al. 2nd combined working group and management committee meeting of urine and kidney proteomics COST action. Proteomics Clin Appl 2009;3:1017-1022.
40. Mischak H, Kolch W, Aivalotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010; 4:464-478.
41. Spasovski G, Ortiz A, Vanholder R, El Nahas M. Proteomics in chronic kidney disease: the issues clinical nephrologists need an answerfor. Proteomics Clin Appl 2011; 5:233-240.
42. Ioannidis JP. A roadmap for successful applications of clinical proteomics. Proteomics Clin Appl 2011; 5:241-247.
43. Manolis E, Vamvakas S, Isaac M. New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin Appl 2011; 5:248-255.
44. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:5511-5519. (Pubitemid 46890577)